PeptiCol EZgraft in the Extraction Socket Preservation Process After Tooth Extraction

The purpose of this clinical trial is to compare the efficacy and safety of using "PeptiCol EZgraft" in extraction socket preservation procedures against "Regenomer," specifically to evaluate whether PeptiCol EZgraft is more effective in reducing alveolar bone changes compared to Regenomer. The trial aims to assess both the effectiveness and safety of PeptiCol EZgraft in minimizing alveolar bone resorption during the healing process following tooth extraction.

Inclusion criteria

• Adults aged 19 to 75 years.
• Systemically healthy or with mild systemic disease, classified as ASA I or II.
• Planning to place implants in the maxilla or mandible after extraction, or having such plans for the future. If there are multiple extraction sockets, only one socket will be included in the trial, and other areas will follow spontaneous healing or treatment plans.
• The extraction socket area must have more than 50% of the alveolar bone wall remaining.
• Willing to maintain good oral hygiene during the clinical trial.
• Voluntarily decided to participate in the trial and signed the informed consent form.
• Willing to participate for the entire duration of the clinical trial and comply with trial procedures.

Exclusion criteria

• Extensive alveolar bone absorption observed in the extraction socket area.
• Severe periodontal disease or acute periodontal abscess.
• Poor oral hygiene.
• History of bone grafts or implants in the area of the medical device application.
• Mucosal diseases due to autoimmune disorders.
• History of hypersensitivity to collagen preparations.
• Smoking more than 10 cigarettes per day.
• Alcohol or drug addiction.

*The alcohol addiction screening will be conducted using AUDIT-K.

• Use of drugs affecting bone formation within 2 weeks prior to screening (e.g., steroids, bisphosphonates).
• Use of oral or injectable rheumatic medications, including immunosuppressants, within 2 weeks prior to screening.
• History of or current use of oral or injectable bisphosphonates for osteoporosis for more than 12 weeks.
• Uncontrolled bleeding disorders or use of medications affecting blood coagulation.
• Uncontrolled diabetes or hypertension.
• Clinically significant cardiovascular, gastrointestinal, respiratory, endocrine, or central nervous system diseases observed at screening.
• Immune disorders including acquired immunodeficiency syndrome.
• Pregnant or breastfeeding women
• During the clinical trial period, female and male participants who are of childbearing potential must agree to use appropriate contraception from the date of signing the informed consent form until the end of the clinical trial (16 weeks post-procedure). If a female participant becomes pregnant during the trial period, her participation will be discontinued.